Open AccessBioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
Author(s) -
Sari Shiba,
Hisakuni Sekino,
Kaeko Ishiba,
Sanae Yasuda,
Syuhei Inoue,
Ken Kotaka,
Larisa Reyderman,
Naoki Uchida
Publication year - 2020
Publication title -
international journal of clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.363
H-Index - 67
ISSN - 0946-1965
DOI - 10.5414/cp203781
Subject(s) - bioequivalence , perampanel , pharmacology , medicine , bioavailability , pharmacokinetics , adverse effect
Perampanel is an approved anti-seizure drug. A new formulation of perampanel fine granules (FG; 1% perampanel) has been developed for patients who are unable to take tablets. Bioequivalence between the 4-mg FG and tablet perampanel formulations, as well as their safety and tolerability, were assessed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom